Carvykti 1 article

The therapeutic identity of Carvykti is defined by ciltacabtagene autoleucel, with BCMA-directed CAR T-cell therapy providing its principal modality. Mechanistically, the product connects autologous T cells with multiple myeloma and dual BCMA-binding domains, and its clinical or biological context includes 4-1BB costimulatory domain, lentiviral vector transduction and ex vivo T-cell engineering. The named therapy remains distinct from other products that may share dual BCMA-binding domains but use a different intervention design.